Illumina Announces BaseSpace® Pricing for Data Storage and Processing

Breaks Analysis Cost Bottleneck for Next Generation Sequencing Workflow

SAN DIEGO--(BUSINESS WIRE)--Jul. 24, 2012-- Illumina, Inc. (NASDAQ:ILMN) today announced pricing for BaseSpace, the Company’s genomics cloud computing and storage platform. The flexible pricing structure will allow researchers around the world to take advantage of BaseSpace’s industry-leading data storage, analysis, and sharing capabilities.

Every BaseSpace account will now include 1 terabyte (TB) of free storage for Illumina data, enabling MiSeq® system users to store hundreds of runs and HiSeq® system users to store several runs worth of data, providing a risk-free means to get started with the cloud. Included with the 1 terabyte of storage is free alignment and variant detection for all Illumina data, eliminating what is currently one of the more costly steps in sequencing. BaseSpace users will also have the ability to purchase incremental storage from within BaseSpace, in both monthly and annual durations.

In the fall, through BaseSpace Apps, every BaseSpace user will have the ability to run analysis applications on an “as-needed” basis, developed by both open source and third-party developers. These applications can be purchased “on the fly” and per analysis, allowing users to affordably run new analysis strategies without investing in dedicated software or hardware infrastructure. BaseSpace Apps will include a diverse and growing set of industry leading data analysis and visualization applications for both MiSeq and HiSeq data analysis. The price for running a BaseSpace App will be set directly by each developer.

“Illumina is taking huge strides to eliminate the much publicized ‘data deluge’ and data analysis bottleneck. The adoption of BaseSpace thus far has been exciting to watch, with the vast majority of MiSeq systems now connected, and already half of those actively uploading data," said Alex Dickinson, Illumina's Senior Vice President, Cloud Genomics. “Making BaseSpace accessible to more researchers will have far-reaching effects, enabling more investment in understanding biology and less in processing data."

“BaseSpace has made it easy to share data with our collaborators and customers,” said Dr. James Hadfield of the Cambridge Research Institute, United Kingdom. “We are looking forward to the development and integration of analysis tools and to using BaseSpace for HiSeq.”

Already compatible with Illumina’s MiSeq system, BaseSpace will become available for use with the Company’s HiSeq systems early in the fourth quarter of 2012, offering the same benefits of seamless real-time data transfer, assembly and variant detection for fast, high quality genome processing. BaseSpace Apps will also become available to customers in the fourth quarter.

Illumina’s pricing plan for BaseSpace is effective immediately. For more information, visit www.illumina.com/BaseSpace.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected availability dates for certain BaseSpace services and Apps. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Kevin Williams, MD
Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-429-8350
pr@illumina.com